Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML

World News: . []

Innate Pharma SA the LINK  - Euronext Paris FR0010331421 IPH today announced that the LINK  of the TELLOMAK Phase II trial and new preclinical data supporting the potential of LINK  in peripheral T-cell lymphoma PTCL as well...

More news and information about INNATE PHARMA

Published By:

Globe Newswire: 09:00 GMT Wednesday 12th June 2019

Published: .

Search for other references to "innate" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us